Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds in biodefense, oncology and pulmonary disorders. The company’s platform consists of approximately 200 compounds licensed from the University of Colorado (UC) Duke University and National Jewish Health. AEOL 10150 The company’s main compound, AEOL 10150 (10150), is being developed under contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Other Product Candidates The company is also developing 10150 as a MCM for exposure to chemical vesicants (e.g., chlorine gas, sulfur mustard gas and phosgene gas) and nerve agents (e.g., sarin gas and soman gas) with grant money from the National Institutes of Healh (NIH) Countermeasures Against Chemical Threats (NIH-CounterACT) program. The company is also developing 10150 for use in combination with radiation therapy for cancer as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control. The company is also developing 10150 for the treatment of lung fibrosis, including idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. This new development program was created based upon the data generated from animal studies in Lung-ARS and chemical gas exposure under the BARDA Contract and NIH grants. Strategy The company’s strategy is to use non-dilutive capital wherever possible to develop its promising platform of broad-spectrum, catalytic antioxidant compounds in important unmet medical indications of clinical and national strategic importance. Research and Development The company’s expenditures related to research and development activities included $6,966,000, as of September 30, 2014. Patents and Proprietary Rights As of December 20, 2013, the company’s catalytic antioxidant small molecule technology base is described in 12 issued United States patents and 5 United States pending patent applications. These patents and patent applications cover soluble manganic porphyrins as antioxidant molecules, as well as targeted compounds obtained by coupling such antioxidant compounds to molecules that bind to specific extracellular elements. The pending U.S. patent applications and issued U.S. patents include composition of matter claims and method claims for several series of compounds. Corresponding international patent applications have been filed, 88 of which have issued, and 1 of which has been allowed to the company, as of December 20, 2013. In 2013, the company filed a provisional patent application with the United States Patent and Trademark Office entitled ‘Synthesis and Formulation of Porphyrin Compounds’. In 2014, a patent application was filed under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO), thereby preserving the right to seek patent protection in all PCT contracting States. History Aeolus Pharmaceuticals, Inc. was founded in 1994. The company was incorporated in the state of Delaware in 1994.
aeolus pharmaceuticals inc
26361 Crown Valley Parkway
Mission Viejo, CA 92691
|No competitor information is available for AOLS.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact AEOLUS PHARMACEUTICALS INC, please visit www.aeoluspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.